Assignee
ASCENDIS PHARMA GROWTH DISORDERS AS
DK·13 granted patents·16 pending applications·78 citations·filing 2016–2024
Top patents by PatentIndex Score
29 records- 0197US11154593B2CNP prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2021·Granted Oct 26, 2021·13 cites·28 claims
- 0297US10835578B2CNP prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Nov 17, 2020·21 cites·20 claims
- 0395US12156917B2CNP prodrugs with carrier attachment at the ring moietyASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Granted Dec 3, 2024·2 cites·13 claims
- 0493US12083182B2Controlled-release CNP agonists with increased NEP stabilityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2021·Granted Sep 10, 2024·3 cites·15 claims
- 0590US11389510B2Controlled-release CNP agonists with low initial NPR-B activityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Jul 19, 2022·5 cites·6 claims
- 0689US11413351B2CNP prodrugs with carrier attachment at the ring moietyASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Aug 16, 2022·7 cites·17 claims
- 0789US2025127859A1Cnp prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 0888US12239689B2Controlled-release CNP agonists with low initial NPR-B activityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Granted Mar 4, 2025·1 cites·10 claims
- 0988US11389511B2Controlled-release CNP agonists with reduced side-effectsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Jul 19, 2022·7 cites·16 claims
- 1088US11224661B2Controlled-release CNP agonists with increased NEP stabilityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Jan 18, 2022·7 cites·13 claims
- 1187US2025090671A1Cnp prodrugsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 1286US11564974B2Combination therapy with controlled-release CNP agonistsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Jan 31, 2023·6 cites·7 claims
- 1386US2024316153A1Cnp prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 1485US11311604B2Controlled-release CNP agonists with low NPR-C bindingASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Apr 26, 2022·6 cites·10 claims
- 1582US2025121074A1Cnp prodrugs with carrier attachment at the ring moietyASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 1677US2022296682A1Cnp prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2021·Application pending·0 cites
- 1777US2025090639A1Controlled-release cnp agonists with low initial npr-b activityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 1876US2025041431A1Controlled-release cnp agonists with increased nep stabilityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 1973US2023116746A1Cnp prodrugsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Application pending·0 cites
- 2072US2021077584A1Cnp prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2020·Application pending·0 cites
- 2170US12544428B2Controlled-release CNP agonists with reduced side-effectsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Granted Feb 10, 2026·0 cites·13 claims
- 2268US2023302091A1Combination Therapy with Controlled-Release CNP AgonistsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Application pending·0 cites
- 2366US2021069339A1Cnp prodrugsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2020·Application pending·0 cites
- 2463US2025032585A1Effective Doses of CNP ConjugatesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Application pending·0 cites
- 2563US2022211817A1Controlled-release cnp agonists with low npr-c bindingASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Application pending·0 cites
- 2661US2025195617A1Liquid Pharmaceutical Formulations of CNP CompoundsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2023·Application pending·0 cites
- 2759US2019255183A1Cnp prodrugsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2019·Application pending·0 cites
- 2850US2017368189A1Cnp prodrugsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2016·Application pending·0 cites
- 2946US12377133B2Dry pharmaceutical formulations of CNP conjugatesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2020·Granted Aug 5, 2025·0 cites·26 claims
Join the waitlist — get patent alerts
Get an alert when ASCENDIS PHARMA GROWTH DISORDERS AS files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →